GlassScriptPhysician profile
Asma A Ahmad
NPI 1093781353
$5,600.07
in general payments reported to CMS, 2019-2025
35 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $633 · 2021: $921 · 2022: $782 · 2023: $955 · 2024: $675 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,229.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,037.32 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $768.14 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $322.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.17 | 2022-2023 | Xifaxan |
| Amgen INC. | $214.94 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.21 | 2019-2025 | Jardiance |
| Pfizer INC. | $177.87 | 2020-2025 | |
| Allergan, INC. | $134.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $124.76 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
| Astellas Pharma US INC | $100.72 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $86.07 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $76.09 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $59.25 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.98 | 2020-2021 | |
| Hologic Sales and Service, LLC | $52.96 | 2025 | Aptima |
| Shield Therapeutics INC | $46.07 | 2022-2024 | |
| Amarin Pharma, INC. | $45.21 | 2021 | |
| Shire North American Group INC | $44.79 | 2019 | |
| Corcept Therapeutics | $44.13 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $38.96 | 2020-2021 | |
| Esperion Therapeutics, INC. | $34.27 | 2024-2025 | Nexletol |
| Arbor Pharmaceuticals, INC. | $32.15 | 2019-2022 | |
| Harmony Biosciences LLC | $29.21 | 2023 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $28.72 | 2022 | |
| Eisai INC. | $28.02 | 2019 | |
| Currax Pharmaceuticals LLC | $27.54 | 2022 | |
| Optinose US, INC. | $27.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.37 | 2020 | |
| Cook Medical LLC | $16.54 | 2025 | Zilver Ptx |
| Sanofi-Aventis U.S. LLC | $16.37 | 2019 | |
| Electromed, INC. | $14.47 | 2021 | |
| Radius Health, INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.